Table 4.

Adverse Events Reported Following a Single Subcutaneous or Intravenous Administration

	Group
	A	B	C	D	E
Adverse Event	N (%)	N (%)	N (%)	N (%)	N (%)
Total number of subjects with at least 1 adverse event	6 (50.0)	5 (41.7)	4 (33.3)	3 (25.0)	4 (33.3)
Upper respiratory tract infection	3 (25.0)	2 (16.7)	1 (8.3)	1 (8.3)	1 (8.3)
Acute sinusitis	0 (0.0)	1 (8.3)	0 (0.0)	0 (0.0)	0 (0.0)
Acute tonsillitis	1 (8.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Conjunctivitis	0 (0.0)	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)
Nasopharyngitis	0 (0.0)	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)
Paronychia	0 (0.0)	1 (8.3)	0 (0.0)	0 (0.0)	0 (0.0)
Pharyngitis	0 (0.0)	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)
Abdominal pain	1 (8.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Aphthous stomatitis	0 (0.0)	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)
Dental caries	0 (0.0)	1 (8.3)	0 (0.0)	0 (0.0)	0 (0.0)
Oropharyngeal pain	0 (0.0)	1 (8.3)	0 (0.0)	0 (0.0)	1 (8.3)
Punctate keratitis	0 (0.0)	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)
Facial pain	1 (8.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Venomous sting	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	0 (0.0)
Blood glucose decreased	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (8.3)
Myalgia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (8.3)
Cervicobrachial syndrome	1 (8.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Dermatitis contact	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	0 (0.0)
Hot flush	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	0 (0.0)